Loading...
NPI 1740715333 · Houston, TX · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Altru Diagnostics, Inc is a clinical medical laboratory provider located in Houston, Texas. This profile covers 117 Medicare and 129 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Altru Diagnostics, Inc |
| Address | 8566 Katy Fwy Ste 121 |
| City | Houston |
| State | TX |
| ZIP | 77024 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | April 21, 2017 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $16.6M |
| Medicaid | $5.1M |
ALTRU DIAGNOSTICS, INC’s billing mix identifies it as a high-throughput molecular clinical laboratory focused on amplified nucleic acid probe testing: its top Medicare revenue drivers are 87798, 87801, and 87150 (all described as amplified probe techniques for infectious agents), and it also reports volume on SARS–CoV–2-specific codes such as U0003 and U0005. The predominance of these molecular and multiplex respiratory codes implies operational capacity and workflows centered on nucleic acid–based testing rather than primarily on routine chemistry or anatomic pathology services.
Revenue concentration on Medicare is heavily weighted toward three molecular codes: 87798 accounts for $6.4M (40.6%), 87801 for $3.2M (20.1%), and 87150 for $3.1M (19.9%), with the top 3 Medicare codes together accounting for 80.6% of the provider’s Medicare revenue. This level of concentration indicates the provider’s Medicare business is dependent on a narrow set of high-volume molecular tests.
On the Medicaid side the provider’s revenue is likewise concentrated in a few test types: U0003 generates $2.2M (44.7%), 87632 contributes $491.1K (9.9%), and U0005 contributes $422.6K (8.6%); the top 3 Medicaid codes collectively account for 63.2% of Medicaid revenue. These figures show Medicaid business is primarily driven by SARS–CoV–2 high‑throughput testing and multiplex respiratory panels rather than broad outpatient lab panels.
Medicare is the larger payer for this provider in scale: total Medicare revenue is $16.6M compared with total Medicaid revenue of $5.1M, indicating the provider’s overall Medicare business materially exceeds its Medicaid business. The presence of meaningful Medicaid volume, however, shows the provider services both public programs rather than being effectively single‑payer.
ALTRU’s competitive standing on its largest Medicare molecular codes is national market leadership: 87798 ranks #4 of 1319 providers and is described as an "extreme outlier, far above typical national volume," 87801 ranks #2 of 561 ("extreme outlier"), and 87150 ranks #5 of 190 ("extreme outlier"). Those ranks and labels indicate the provider is a dominant national performer for several specific amplified nucleic acid probe assays rather than a modest participant.
State-level positioning on Medicaid shows strong in‑state presence for SARS–CoV–2 testing and specimen collection: U0003 represents a large share of Medicaid revenue ($2.2M, 44.7%) and is reported as "typical, unremarkable volume" for the code, while G2023 specimen collection ($318.4K, 6.4%) ranks #6 in‑state and is labeled an "extreme outlier, far above typical state volume." Together these entries imply the provider handles substantial specimen throughput in‑state even where per-claim reimbursement is modest.
Although molecular infectious testing dominates, ALTRU also bills routine clinical assays at much lower revenue levels—examples on Medicare include 84443 (TSH) at $96.5K (0.6%), 80053 (CMP) at $82.6K (0.5%), and 80061 (lipid panel) at $79.7K (0.5%). These smaller but diverse code entries indicate a residual, conventional laboratory service mix alongside the core molecular testing platform.
The provider’s NPI was enumerated on 2017-04-21 (~9 years ago), establishing nearly a decade of billing activity; the combination of tenure and the extreme‑outlier ranks on multiple molecular codes suggests the organization has scaled molecular test volume rapidly since enumeration to reach national and in‑state prominence for specific assays.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
117 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 187,150 | $30 | $6.4M |
| 87801 | The lab analyst performs a test for multiple infectious agents using amplified nucleic acid probe technique. | 45,710 | $70 | $3.2M |
| 87150 | The lab analyst performs an analysis using amplified DNA or RNA probe technique on a previously isolated and identified organism to categorize the organism more specifically, such as to the taxonomic… | 91,750 | $30 | $3.1M |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 16,890 | $30 | $574.1K |
| 87653 | The lab analyst performs a test for Streptococcus, group B, using amplified nucleic acid probe technique. The amplified probe provides a rapid means to assess colonization by Streptococcus, group B,… | 15,250 | $30 | $518.5K |
| 87500 | The lab analyst performs a test for vancomycin resistance in an infectious organism’s nucleic acid using amplified probe technique. VRE, vancomycin resistant enterococcus, is the most common organism… | 9,410 | $30 | $319.9K |
| 87641 | The lab analyst performs a test for methicillin–resistant Staphylococcus aureus (MRSA) using an amplified nucleic acid probe technique. | 9,410 | $30 | $319.8K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 2,700 | $70 | $199.4K |
| 84443 | The lab analyst performs a test to measure the amount of thyroid–stimulating hormone (TSH), a hormone produced in the pituitary gland that helps regulate thyroid function. The typical specimen is the… | 6,030 | $20 | $96.5K |
| 80053 | The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel. | 8,260 | $10 | $82.6K |
Showing 1–10 of 117
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 117 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
117 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| 87150 | 2 | 30 | 1,260 | $30 | $430.3K |
| 87637 | 5 | 70 | 40 | $140 | $404.2K |
| 87798 | 2 | 300 | 790 | $30 | $265.1K |
| 87631 | 12 | 90 | 50 | $140 | $90.1K |
| 87801 | 1 | 120 | 170 | $70 | $86.5K |
| 87536 | 8 | 10 | 560 | $80 | $75.8K |
| P9603 | 15 | 30 | 26,220 | $1 | $73.2K |
| 87481 | 7 | 270 | 150 | $30 | $68.8K |
| U0003 | 4 | 60 | 100 | $70 | $64.7K |
| 81418 | 2 | 10 | 300 | $170 | $51.6K |
Showing 1–10 of 117
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
129 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 66,910 | $30 | $2.2M |
| 87632 | The lab analyst performs a test to identify a respiratory virus using an amplified nucleic acid probe technique. He may also use the multiplex reverse transcription technique. The provider does this… | 10,680 | $50 | $491.1K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 42,260 | $10 | $422.6K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 31,840 | $10 | $318.4K |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 21,850 | $10 | $284K |
| 87631 | The lab analyst performs the technical steps to detect three to five types or subtypes of pathogens, such as adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus,… | 6,080 | $30 | $194.6K |
| 87633 | The lab analyst performs a test to identify a respiratory virus using amplified nucleic acid probe technique. He may also use a multiplex reverse transcription technique. The provider does this for… | 1,650 | $90 | $155K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 2,880 | $50 | $129.7K |
| 87637 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, influenza B, and respiratory syncytial virus (RSV)… | 1,480 | $70 | $108K |
| 87640 | The lab analyst performs the technical lab test to look for Staphylococcus aureus nucleic acid using an amplified probe technique. | 17,050 | $10 | $102.3K |
Showing 1–10 of 129
How this provider's Medicaid billing volume and revenue compare to other Texas providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Texas median
129 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 9 | 340 | 400 | $50 | $553.5K |
| 87637 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, influenza B, and respiratory syncytial virus (RSV)… | 26 | 120 | 340 | $120 | $422K |
| 87632 | The lab analyst performs a test to identify a respiratory virus using an amplified nucleic acid probe technique. He may also use the multiplex reverse transcription technique. The provider does this… | 2 | 20 | 180 | $170 | $362.6K |
| 81408 | The lab analyst performs the technical lab test to complete one of the specific genetic analyses listed in this Tier 2, Level 9 molecular pathology code. | 17 | 40 | 100 | $230 | $335.3K |
| 87633 | The lab analyst performs a test to identify a respiratory virus using amplified nucleic acid probe technique. He may also use a multiplex reverse transcription technique. The provider does this for… | 23 | 160 | 200 | $280 | $321.8K |
| 80050 | The lab analyst performs testing for the specific group of clinical laboratory procedures in the general health panel. Payers typically consider 80050 to apply only when the clinician orders the… | 9 | 150 | 170 | $30 | $302.9K |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 7 | 240 | 420 | $30 | $296.8K |
| 87591 | The lab analyst performs a lab test for Neisseria gonorrhoeae, also called GC, using amplified nucleic acid probe technique. | 190 | 290 | 410 | $20 | $225K |
| 87491 | The lab analyst performs a test for Chlamydia trachomatis using amplified nucleic acid probe technique. | 197 | 300 | 410 | $20 | $223.4K |
| 87631 | The lab analyst performs the technical steps to detect three to five types or subtypes of pathogens, such as adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus,… | 9 | 140 | 180 | $60 | $215.9K |
Showing 1–10 of 129
Other providers in the same ZIP code as Altru Diagnostics, Inc, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Memorial Hermann Hospital Based Physician Group | TX | Emergency Medicine Physician | $0 | $27.4M |
| Central Home Health Services Of Texas, LLC | TX | Home Health Agency | $0 | $16.9M |
| Spring Branch Isd | TX | Local Education Agency (LEA) | $0 | $12.2M |
| Philip Blum | TX | Neurology Physician | $2.5M | $0 |
| Kevin Lisman | TX | Cardiovascular Disease Physician | $2.1M | $0 |
| Ronjay Rakkhit | TX | Hematology & Oncology Physician | $1.6M | $0 |
| Hedwig Asc | TX | Ambulatory Surgical Clinic/Center | $1.4M | $0 |
| Todd Price | TX | Specialist | $1.1M | $0 |
| Greg Pearson | TX | Dermatology Physician | $890.6K | $0 |
| Sohail Jalal | TX | Clinical Cardiac Electrophysiology Physician | $579.1K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.